Is NCT05805709 recruiting in Baltimore, MD?

Yes, NCT05805709 is currently recruiting participants at its Baltimore, MD location. This acute kidney injury clinical trial is actively enrolling qualified participants.

How do I join the acute kidney injury clinical trial in Baltimore?

To join this clinical trial in Baltimore, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Baltimore clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Acute Kidney Injury Clinical Trial in Baltimore, MD

About This Acute Kidney Injury Study in Baltimore

The COPE-AKI study is a randomized, pragmatic, parallel-arm trial comparing a multimodal intervention to usual care on hospital-free days through 90 days of study follow up. The primary study hypothesis is that patients randomized to the intervention will have increased odds of more hospital-free days through 90 days (primary clinical) compared to those randomized to usual care. Key secondary hypotheses will investigate the impact of the intervention on rates of major adverse kidney events, rates of recurrent AKI, and changes in patient-reported outcomes. Participants (N=2145) will be allocated 1:1 to the intervention or usual care using a web-based system to maintain allocation concealment using stratified randomization with randomly permuted blocks. Randomization will be stratified by clinical site.

Sponsor: University of Pittsburgh

Who Can Participate

Inclusion Criteria

Aged ≥ 18 years

Kidney Disease Improving Global Outcomes (KDIGO) Stage 2/3 AKI with evidence of persistent AKI (defined as meeting Stage 2+ AKI for 2 consecutive days with serum creatinine concentration measurements \>12 hours apart)

Exclusion Criteria

AKI due to primary glomerulonephritis, renal vasculitis, or thrombotic microangiopathy

Diagnosis of end-stage kidney disease (ESKD) at the time of admission, defined as:

Baseline estimated glomerular filtration rate (eGFR) \<15 mL/min/1.73m2

Previous kidney transplant recipient

On chronic dialysis

Acute urinary obstruction with rapid kidney function improvement following relief of obstruction

Index hospitalization involving nephrectomy

Index hospitalization involving solid organ transplant or stem cell/bone marrow transplant

Continued dialysis dependence at time of discharge

Previous (within 6 months) or new referral to a nephrologist for care specifically for:

Previous or new diagnosis of glomerulonephritis

Primary electrolyte imbalance disorders unrelated to AKI (e.g., syndrome of inappropriate antidiuretic hormone secretion, Bartter syndrome)

Active treatment for acute interstitial nephritis

Non-kidney end-organ failure:

Class IV congestive heart failure

Decompensated cirrhosis with Model For End-Stage Liver Disease (MELD) \> 30 or those with a diagnosis of hepatorenal syndrome by the clinical teams

End-stage pulmonary disease (advanced stage chronic obstructive pulmonary disease, interstitial lung disease, cystic fibrosis, pulmonary hypertension)

Metastatic malignancy or malignancy requiring active treatment (chemotherapy, immunotherapy), such as multiple myeloma

Primary goal of care is palliation: life expectancy \<6 months

Vulnerable populations

Persons incarcerated

Persons institutionalized

Inability to provide informed consent a. Impaired cognition as demonstrated by the Brief Confusion Assessment Method (bCAM)

Concurrent enrollment in a separate greater than minimal risk interventional trial

Inability to participate in either in-person or remote visits a. Inability to participate as determined by the research team at time of discharge based on disposition (vs uniform decision across site about exclusion based on SNF)

Discharge to long-term acute care facility or other hospital-based location

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Baltimore?

Yes, this clinical trial (NCT05805709) has an active research site in Baltimore, MD that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Acute Kidney Injury Treatment Options in Baltimore, MD

If you're searching for acute kidney injury treatment options in Baltimore, MD, this clinical trial (NCT05805709) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Baltimore research site is actively enrolling participants for this clinical trial. You'll receive care from experienced acute kidney injury specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Acute Kidney Injury Clinical Trial in Baltimore, MD

Expert Care in Baltimore

IRB Approved

No-Cost Care

Apply for This Baltimore Location

Why Participate?

Simple Process